Literature DB >> 28215731

Complementopathies.

Andrea C Baines1, Robert A Brodsky2.   

Abstract

The complement system is an essential part of the innate immune system that requires careful regulation to ensure responses are appropriately directed against harmful pathogens, while preventing collateral damage to normal host cells and tissues. While deficiency in some components of the complement pathway is associated with increased susceptibility to certain infections, it has also become clear that inappropriate activation of complement is an important contributor to human disease. A number of hematologic disorders are driven by complement, and these disorders may be termed "complementopathies". This includes paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), cold agglutinin disease (CAD) and other related disorders, which will be the focus of this review. A better understanding of the central role of the complement system in the pathophysiology of these disorders may allow for application of therapies directed at blocking the complement cascade.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alternative pathway of complement; Atypical hemolytic uremic syndrome; Cold agglutinin disease; Complementopathy; HELLP syndrome; Paroxysmal nocturnal hemoglobinuria

Mesh:

Substances:

Year:  2017        PMID: 28215731      PMCID: PMC5513767          DOI: 10.1016/j.blre.2017.02.003

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  98 in total

1.  A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome.

Authors:  Tara K Maga; Nicole C Meyer; Craig Belsha; Carla J Nishimura; Yuzhou Zhang; Richard J H Smith
Journal:  Nephrol Dial Transplant       Date:  2010-10-25       Impact factor: 5.992

2.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Authors:  Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 3.  Paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

4.  Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

Authors:  Fadi Fakhouri; Lubka Roumenina; François Provot; Marion Sallée; Sophie Caillard; Lionel Couzi; Marie Essig; David Ribes; Marie-Agnès Dragon-Durey; Frank Bridoux; Eric Rondeau; Veronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 10.121

5.  Modified Ham test for atypical hemolytic uremic syndrome.

Authors:  Eleni Gavriilaki; Xuan Yuan; Zhaohui Ye; Alexander J Ambinder; Satish P Shanbhag; Michael B Streiff; Thomas S Kickler; Alison R Moliterno; C John Sperati; Robert A Brodsky
Journal:  Blood       Date:  2015-04-10       Impact factor: 22.113

6.  Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.

Authors:  Janus Asbjørn Schatz-Jakobsen; Yuchun Zhang; Krista Johnson; Alyssa Neill; Douglas Sheridan; Gregers Rom Andersen
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

7.  Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome.

Authors:  Patrick J Gleeson; Valerie Wilson; Thomas E Cox; Seema D Sharma; Kate Smith-Jackson; Lisa Strain; David Lappin; Teresa McHale; David Kavanagh; Timothy H J Goodship
Journal:  Immunobiology       Date:  2016-05-10       Impact factor: 3.144

8.  Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Tommaso Rondelli; Antonio M Risitano; Régis Peffault de Latour; Michela Sica; Benedetta Peruzzi; Patrizia Ricci; Wilma Barcellini; Anna Paola Iori; Carla Boschetti; Veronica Valle; Veronique Frémeaux-Bacchi; Maria De Angioletti; Gerard Socie; Lucio Luzzatto; Rosario Notaro
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

9.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113

10.  Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak.

Authors:  Tammy M Brady; Cozumel Pruette; Lauren F Loeffler; Darcy Weidemann; John J Strouse; Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Exp Nephrol       Date:  2016-05-06
View more
  34 in total

Review 1.  Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.

Authors:  Samuel A Merrill; Robert A Brodsky
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.

Authors:  Shruti Chaturvedi; Evan M Braunstein; Robert A Brodsky
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

3.  Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.

Authors:  Ulrich Jäger; Shirley D'Sa; Christian Schörgenhofer; Johann Bartko; Ulla Derhaschnig; Christian Sillaber; Petra Jilma-Stohlawetz; Michael Fillitz; Thomas Schenk; Gary Patou; Sandip Panicker; Graham C Parry; James C Gilbert; Bernd Jilma
Journal:  Blood       Date:  2018-12-17       Impact factor: 22.113

Review 4.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 5.  The Complement System and Preeclampsia.

Authors:  Jean F Regal; Richard M Burwick; Sherry D Fleming
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 6.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

Review 7.  The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation.

Authors:  Kalpana Manthiram; Qing Zhou; Ivona Aksentijevich; Daniel L Kastner
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

8.  Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Ulla Derhaschnig; Nina Buchtele; Christian Sillaber; Michael Fillitz; Thomas M Schenk; Shirley D'Sa; Ronwyn Cartwright; James C Gilbert; Bernd Jilma; Ulrich Jaeger
Journal:  Blood Adv       Date:  2020-03-24

Review 9.  Dominant C3 glomerulopathy: new roles for an old actor in renal pathology.

Authors:  Nicola Pirozzi; Antonella Stoppacciaro; Paolo Menè
Journal:  J Nephrol       Date:  2017-11-18       Impact factor: 3.902

10.  Treatment of Autoimmune Diseases with Therapeutic Antibodies: Lessons Learned from PID Patients Allow for Stratification of the Infection Risk.

Authors:  Joyce J B C van Beers; Jan G M C Damoiseaux
Journal:  Methods Mol Biol       Date:  2022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.